Euronext Amsterdam to become Market of Reference for Galapagos
March 21 2014 - 6:46AM
- Single order book and price discovery to move from
Brussels to Amsterdam
- Dual listing on Euronext Brussels and Euronext
Amsterdam remains intact
- No impact on ISIN, GLPG ticker symbol, or settlement
mechanics
Galapagos NV (Euronext: GLPG) announced today that the
market of reference will change from Euronext Brussels to Euronext
Amsterdam, effective as of 28 March 2014. The change of market of
reference means that orders in Galapagos' securities will be
gathered and centrally administered in the single order book in
Euronext Amsterdam.
The change of market of reference does not
impact Galapagos' organization (including its Mechelen legal
headquarters), its Belgian presence, or activities.
Furthermore,Galapagos' dual listing on Euronext Brussels and
Euronext Amsterdam, the ISIN (BE0003818359), the ticker symbol
(GLPG), and clearing and settlement mechanics will all remain
unchanged.
"Galapagos has been listed on Euronext Amsterdam
and Euronext Brussels since the IPO in 2005. Since the
implementation of the single order book in 2009, Galapagos' market
of reference has been Euronext Brussels. The change of Market
of Reference to Euronext Amsterdam is intended to bring Galapagos'
exposure to Dutch investors more in line with the high level of
exposure the Company has in Belgium," said Elizabeth Goodwin, Head
of Corporate Communications and Investor Relations at
Galapagos.
Market parties and information services will be
informed in due course as the implementation is prepared. The
target effective date for the change of market of reference is 28
March 2014.
About Galapagos Galapagos
(Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising five Phase 2
studies (two led by GSK), one Phase 1 study, six pre-clinical, and
20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and in Phase 2 in Crohn's disease.
Galapagos has another selective JAK1 inhibitor in Phase 2 in
ulcerative colitis and psoriasis, GSK2586184 (formerly GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0974 is the
first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept
Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and has completed Phase 1.
AbbVie and Galapagos signed an agreement in CF whereby they
work collaboratively to develop and commercialize oral drugs that
address two mutations in the CFTR gene, the G551D and F508del
mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. Galapagos has 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Elizabeth Goodwin, Head of Corporate
Communications & Investor Relations Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
HUG#1770353
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Oct 2023 to Oct 2024